News Snapshot:
United Biomedical Inc Asia (UBI, 聯亞生技) has reapplied for emergency use authorization (EUA) for its COVID-19 vaccine candidate after an attempt last year to get one fell through. An EUA request for the company’s UB-612 product was delivered to the Food and Drug Administration (FDA) on Monday, the company said in a statement yesterday. The company said that it is analyzing data from its second clinical trial and planning for a phase 3 clinical trial is ongoing. Photo: Screen grab from the Web site of United Biomedical Inc Asia The original EUA request was rejected on Aug. 16 last year...
